期刊文献+

慢性淋巴细胞白血病患者血清TGF-β、IL-17、IL-4及IFN-γ水平变化及其临床意义 被引量:6

The level and its clinical significance of TGF-β,IL-17,IL-4 and IFN-γ in serum of patients with chronic lymphocytic leukemia
下载PDF
导出
摘要 目的探讨慢性淋巴细胞白血病(CLL)患者血清转化生长因子-β(TGF-β)、白介素-17(IL-17)、白介素-4(IL-4)及干扰素-γ(IFN-γ)水平变化及其临床意义。方法选取确诊为CLL患者60例为初诊CLL组,20例健康人作为对照组,并对32例患者进行了治疗随访(治疗后组),用ELISA技术检测血清IL-17、TGF-β、IL-4和IFN-γ及其比值的变化。结果初诊CLL组患者外周血IL-17、TGF-β、IL-4、TGF-β/IL-17比值均高于对照组(P<0.05),IFN-γ及IFN-γ/IL-4比值均低于对照组(P<0.05),治疗后组TGF-β、IL-17、IL-4及TGF-β/IL-17均低于初诊CLL组(P<0.05),IFN-γ及IFN-γ/IL-4高于初诊CLL组(P<0.05)。在Binet A期、B期、C期分期中,TGF-β/IL-17比值逐渐增高,其中C期高于A期和B期(P<0.05),IFN-γ/IL-4比值逐渐减低(P<0.05),初诊CLL组患者TGF-β/IL-17及IFN-γ/IL-4比值与Binet分期均呈正相关。结论随着疾病的进展,CLL患者细胞因子IFN-γ/IL-4和TGF-β/IL-17的格局发生变化,TGF-β/IL-17比值逐渐增高,IFN-γ/IL-4比值逐渐减低,IFN-γ/IL-4和TGF-β/IL-17的比值可能可以作为CLL患者疾病进展及预后评价指标之一。 Objective To investigate the clinical significance of TGF-β,IL-17,IL-4 and IFN-γ level in serum of patients with chronic lymphocytic leukemia( CLL). Methods The study enrolled 20 healthy individuals and 60 CLL patients. 32 patients were received treatment and followed-up. ELISA was used to measure the level of transformation growth factor-β( TGF-β),interleukin-17( IL-17),interleukin-4( TGF-β,IL-4),interferon-γ( IFN-γ)in the serum of the every group. Results( 1) The level of IL-17,TGF-β,IL-4 and the ratio of TGF-β / IL-17 in peripheral blood of first visit CLL patients group were higher than those in the control group( P〈0. 05). The level of IFN-γ and the ratio of IFN-γ / IL-4 were lower than those in the control group( P〈0. 05). Compared with the CLL group,the treated cases had the lower level of TGF-β,IL-17,IL-4 and TGF-β / IL-17( P〈0. 05). The ratio of IFN-γ and IFN-γ / IL-4 in treated cases was higher( P〈0. 05) than that in the CLL group.( 2) In stage of Binet A,B,C,the later stage the higher ratio of TGF-β / IL-17 and the ratio of TGF-β / IL-17 in stage Binet C was higher than that in stage Binet A and Binet B( P〈0. 05). In the later the stage,the the ratio of IFN-γ / IL-4 decreased gradually( P〈0. 05). The ratio of IFN-γ and IFN-γ / IL-4 were positively correlated with the clinical Binet stages in first visit CLL group. Conclusion With the progression of disease,the ratio of TGF-β / IL-17 and IFN-γ / IL-4were changed in CLL patients.,With the progression of the disease,the ratio of TGF-β / IL-17 increased gradually,and the ratio of IFN-γ / IL-4 decreased gradually. The ratio of TGF-β / IL-17 and IFN-γ / IL-4 might be one of the evaluation index for disease progression and prognosis of in patients with CLL.
出处 《新疆医科大学学报》 CAS 2016年第2期210-214,共5页 Journal of Xinjiang Medical University
基金 新疆维吾尔自治区自然科学基金(2013211A100)
关键词 慢性淋巴细胞白血病 血清转化生长因子-β/白介素-17 干扰素-γ/白介素-4 预后 chronic lymphocytic leukemia(CLL) TGF-β / IL-17 IFN-γ / IL-4 progression prognosis
  • 相关文献

参考文献23

  • 1Chiorarzi N, Rai KR,Ferrarini M, et al. Chronic lymphocytic leukemia[J].N Engl J Med,2005,352(8) :804-815.
  • 2Hojjat-Farsangi M, Jeddi-Tehrani M, Raravi SM, et al.Immu- noglobulin heavy chain variable region gene usage and muta- tional status of the leukemic B ceils in Iranian patients with chronic lymphocytic leukemia [J]. Cancer Sci, 2009,100 (12) : 2346-2353.
  • 3DrArena G, Simeon V ,Auria F, et al. Regulatory T-cells in chronic lymphocytic leukemia : actor or innocent bystander[J]. Am J Blood Res,2013,3(1) :52-57.
  • 4Dr Arena G, Rossi G, Vannata B, et ah Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases[J]. Meditrr J Hematol Infect Dis,2012,4(1) :136-141.
  • 5Salluto F, Lanzavecchia A. Heterogeneity of CD4 + memory T cells: functional modules for tailored immunity [J]. Eur J Im- munol, 2009,39 (8) : 2076-2082.
  • 6Podhorecka M, Dmoszynska A, Rolinski J, et al. T type1/ type2 subsets balance in B-cell chronic lymphocytic leukemia- the three-color flow cytometry analysis[J]. Leuk Res, 2002, 26(7) :657-660.
  • 7Iwona H, Agnieszka B, Sylwia C, et al. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity[J]. PLoS One,2013,8(11) :256-259.
  • 8Jadidi F, Ghalamfarsa G, Memarian A, et al. Downregulation of IL-17-producing T cells is associated with regulatory T cell ex- pansion and disease progression in chronic lymphocytic leukemia[J].Tumour Biol, 2013,34(2) : 929- 940.
  • 9余静静,陈刚,庞楠楠,郭新红,王蕾,赵芳,谭明芳,曲建华.不同分期慢性淋巴细胞白血病患者外周血T-bet、GATA-3、RORγt和Foxp3 mRNA的表达变化[J].中国实验血液学杂志,2015,23(1):45-49. 被引量:7
  • 10张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2012:139-143.

二级参考文献33

  • 1D'Arena G, Simeon V, D'Auria F, et al. Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander[ J ] ? Am J Blood Res, 2013, 3(1) : 52 -57.
  • 2Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4 + T cell repertoire towards a regulatory phenotype and leads to the accumulation of CIM + forkhead box P3 + T cells [ J ]. Clin Exp Immunol, 2011, 166 (2) : 154 - 163.
  • 3Jadidi-Niaragh F, Ghslamfarsa G, Yousefi M, et al. Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions[J]. Tumour Biol, 2013, 34(4) : 2031 -2039.
  • 4D'Arena G, Simeon V, De Martino L, et al. Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia [ J ]. Int J Immtmophthol Pharmacol, 2013, 26( 1 ) : 117 - 125.
  • 5D'Arena G, Rossi G, Vannata B, et al. Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases [ J/OA ]. Mediterr J Hematol Infect Dis, 2012, 4( 1 ) : e2012053.
  • 6Jadidi-Niaragh F, Yousefi M, Memarian A, et al. Increased frequency of CI)8 + and CIM+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression [ J]. Cancer Invest, 2013, 31 (2): 121-131.
  • 7Dasgupta A, Mahapatra M, Saxena R, et al. Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3 [ J]. Leuk Lymphoma, 2013,54(4) : 778 -789.
  • 8Lad DP, Varma S, Varma N, et al. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias[ J] . Leuk Lymphoma, 2013, 54 (5) : 1012 -1019.
  • 9Biancotto A, Dagur PK, Fuchs JC, et al. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia [J]. Mod Pathol, 2012, 25(2) : 246 -259.
  • 10Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia [J]. Cancer, 2011, 117(10) : 2163 -2169.

共引文献17

同被引文献50

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部